New cocktail of cancer drugs tested in desperate cases
NCT ID NCT01552434
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested combinations of the drugs bevacizumab and temsirolimus, sometimes with valproic acid or cetuximab, in 154 people with advanced cancers or certain non-cancerous but progressive diseases. The main goal was to find safe doses and look for any signs that the drugs shrink tumors. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bevacizumab (Avastin) and temsirolimus, alone or with valproic acid or cetuximab
- What this could lead to
- If successful, this could identify safe doses and early signs of tumor shrinkage for these drug combinations in advanced cancers.
- What could go wrong
- This is an early Phase 1 trial focused on safety, not effectiveness. It was terminated, so results may be incomplete. Many drug combinations fail to show benefit in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Digital therapy aims to tame the fear that haunts cancer survivors
- Blood test may one day personalize drug dosing after stem cell transplants
- Can a rapid lab test guide treatment for rare gynecologic cancers?
- New platform trial takes on NF2 tumors with multiple drug strategies